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ABSTRACT
Background Dual antiplatelet therapy (DAPT) has 
important implications for clinical outcomes in coronary 
disease. However, the optimal DAPT duration remains 
uncertain.
Methods and results We searched four major databases 
for randomised controlled trials comparing long- term 
(≥12 months) with short- term (≤6 months) or shorter 
(≤3 months) DAPT in patients with coronary syndromes. 
The primary outcome was all- cause mortality. Secondary 
outcomes were any bleeding and major bleeding (safety), 
cardiac death, myocardial infarction, stent thrombosis, 
revascularisation and stroke (efficacy). Nineteen 
randomised controlled trials (n=60 111) satisfied inclusion 
criteria, 8 assessed ≤3 months DAPT. Compared with 
long- term (≥12 months), short- term DAPT (≤6 months) 
was associated with a trend towards reduced all- cause 
mortality (RR: 0.90, 95% CI: 0.80 to 1.01) and significant 
bleeding reduction (RR: 0.68, 95% CI: 0.55 to 0.83 and 
RR: 0.66, 95% CI: 0.56 to 0.77 for major and any bleeding, 
respectively). There were no significant differences 
in efficacy outcomes. These associations persisted in 
sensitivity analysis comparing shorter duration DAPT (≤3 
months) to long- term DAPT (≥12 months) for all- cause 
mortality (RR: 0.91, 95% CI: 0.79 to 1.05). In subgroup 
analysis, short- term DAPT was associated with lower risk 
of bleeding in patients with acute or chronic coronary 
syndromes (RR: 0.66, 95% CI: 0.54 to 0.81 and RR: 0.53, 
95% CI: 0.33 to 0.65, respectively), but higher risk of stent 
thrombosis in acute coronary syndrome (RR: 1.49, 95% CI: 
1.02 to 2.17 vs RR: 1.25, 95% CI 0.44 to 3.58).
Conclusion Our meta- analysis suggests that short (≤6 
months) and shorter (≤3 months) durations DAPT are 
associated with lower risk of bleeding, equivalent efficacy 
and a trend towards lower all- cause mortality irrespective 
of coronary artery disease stability.
INTRODUCTION
Dual antiplatelet therapy (DAPT) is a central 
component of the modern management of 
acute coronary syndromes (ACS). The aim 
of DAPT is to reduce the risk of recurrent 
atherothrombotic events by suppressing 
thrombus formation related to disrupted 
atherosclerotic plaque.1 2 Despite substantial 
evidence supporting its use, there remains 
major uncertainty regarding the optimal 
duration of therapy. While clinical guidelines 
on the management of ACS recommend a 
default duration of 12 months of DAPT with 
aspirin and a P2Y12 receptor antagonist, they 
also advise consideration of short- term DAPT 
(≤6 months) for patients at a high risk of 
bleeding.3 4
Previous systematic reviews and meta- 
analyses concluded that shorter durations of 
DAPT may be superior to standard care in 
Key messages
What is already known about this subject?
 ► Dual antiplatelet therapy (DAPT) is a central com-
ponent of the modern management of acute and 
chronic coronary syndromes following percutaneous 
coronary intervention. Despite substantial evidence 
supporting its use, there remains major uncertainty 
regarding the optimal duration of therapy.
What does this study add?
 ► Short- term (≤6 months) and shorter durations (≤3 
months) of DAPT are associated with significantly 
lower risk of bleeding, equivalent efficacy and a 
trend towards lower all- cause mortality compared 
with long- term DAPT (≥12 months) irrespective of 
coronary artery stability.
 ► This meta- analysis highlights the paucity of ran-
domised controlled trial evidence to guide DAPT in 
acute coronary syndrome patients who are man-
aged without percutaneous coronary intervention 
such as those receiving medical therapy only or 
those undergoing coronary artery bypass grafting.
How might this impact on clinical practice?
 ► Shorter durations of DAPT in patients with acute or 
chronic coronary syndrome undergoing percutane-
ous coronary intervention may be the best balance 
between efficacy and safety outcomes as shown by 
all- cause mortality which tended to favour 3 months 
of therapy.
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most patients, with apparent small reductions in all- cause 
mortality.5 6 This suggests that the risk of major bleeding 
outweighs any benefit gained from the reduction in 
future atherothrombotic events. These meta- analyses 
reviewed trials which, for the most part, evaluated DAPT 
following percutaneous coronary intervention with 
drug- eluting stents in patients with chronic coronary 
syndromes. Recently, there have been several large- scale 
randomised controlled trials evaluating shorter durations 
of DAPT (≤3 months) in the setting of ACS.7–9
Here, we perform an updated systematic review and 
meta- analysis comparing outcomes in long- term DAPT 
(≥12 months) with short- term (≤6 months) and shorter 
(≤3 months) durations of DAPT incorporating the latest 
randomised controlled trial evidence.
METHODS
Data sources and search strategy
This systematic review and meta- analysis followed the 
Cochrane Collaboration guidelines and the Preferred 
Reporting Items for Systematic Reviews and Meta- 
Analyses (online supplemental research checklist) and 
was performed according to a prespecified analysis plan 
(online supplemental appendix).10 11 Two independent 
investigators (MM and AB) performed the literature 
search using four major databases: Central, Embase, 
Medline and Web of Science from 1950 to February 2020. 
In addition, online resources including  ClinicalTrials. gov 
and proceedings from major cardiovascular conferences 
were also screened. The search strategy was individually 
tailored to each database (online supplemental S1 table). 
Relevant search items such as: ‘coronary syndrome’, ‘anti-
platelet therapy’, ‘platelet aggregation inhibitor’, ‘drug 
eluting stent’, ‘coronary intervention’ were included in 
the Medical Subject Heading search.
Study selection
Randomised controlled trials comparing different 
durations of DAPT, irrespective of presentation (acute 
or chronic coronary syndromes), or the management 
strategy (percutaneous coronary intervention, coronary 
artery bypass graft surgery or medical therapy alone) 
that assessed at least one of the prespecified outcomes of 
interest were included in this systematic review and meta- 
analysis. The DAPT durations of interest were ≤6 months 
(short- term) versus ≥12 months (long- term). Studies 
which compared mid- term DAPT (>6 but<12 months) to 
long- term (≥12 months) or standard term (12 months) 
to longer- term (>18 months) DAPT were excluded.12–15 
Cross- sectional studies, observational studies, case reports 
or case series were also excluded.
Quality assessment and data extraction
Two investigators (MM and AB) independently screened 
article titles and abstracts to exclude any trials which did 
not match the research question of interest. Subsequently, 
the two reviewers independently screened the eligible 
full- text articles to identify randomised controlled trials 
which met the prespecified inclusion criteria. The refer-
ence lists of the relevant studies were manually checked 
to identify potentially missed studies. Data extraction was 
conducted independently by two authors (MM and AB) 
and any conflicts related to data extraction were resolved 
through discussion and review of data or consensus from 
a third author (KKL).
Data extraction included study characteristics (trial 
registration number, trial name, trial period, study 
centre(s), year of publication, first author, randomisa-
tion arms (intervention vs control), study population 
according to randomisation arm, treatment strategy 
according to randomisation arm, randomisation time, 
follow- up duration, outcome measures including primary, 
secondary outcomes and relevant definitions (table 1). 
Baseline characteristics for study population (age, sex, 
ACS at presentation, patients with background history 
of diabetes mellitus, ischaemic heart disease, periph-
eral vascular disease, renal impairment and cardiovas-
cular risk factors) (online supplemental S2 table) were 
collected where available, and relevant risk estimates for 
the primary trial outcome and meta- analysis outcomes of 
interest (online supplemental S3 table).
The study quality was assessed using the Cochrane 
Collaboration tool for assessment of risk of bias, which 
includes random sequence generation; allocation 
concealment; blinding of participants, personnel and 
outcome assessors; incomplete outcome data; selective 
reporting and other sources of bias.16 Disagreements 
were resolved by consensus.
Definition of outcomes
The primary outcome was all- cause mortality and 
secondary efficacy outcomes were cardiac death, myocar-
dial infarction, stent thrombosis, coronary revasculari-
sation and stroke. Secondary safety endpoints were any 
bleeding and major bleeding. Stent thrombosis included 
definite or probable thrombosis according to individual 
trial definitions and criteria from the Academic Research 
Consortium.17 Trial definitions for major and any 
bleeding were applied, and these included the Throm-
bolysis in Myocardial Infarction or Bleeding Academic 
Research Consortium criteria (online supplemental S4 
table).18 19 Randomised controlled trials which did not 
report event rates or risk estimates for the prespecified 
endpoints were not included in the overall meta- analysis 
estimates.
Statistical analysis
In this pairwise meta- analysis, risk estimates and event 
rates for each outcome of interest were extracted from 
the randomised controlled trials. Risk ratios and 95% CI 
were used as summary statistics to evaluate the effect of 
DAPT duration on the outcomes of interest. Pooled meta- 
analysis risk estimates were computed using a random- 
effects model. Risk ratios greater than one represented 
benefit associated with the longer DAPT duration arm 
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(control), and less than one was associated with benefit 
favouring the shorter duration arm (intervention).
Between study heterogeneity was assessed using the 
statistical inconsistency test (I2=100% × (Q−df)/Q, where 
Q= χ2 (Cochran’s heterogeneity statistic) and df=its 
degrees of freedom), where I2 ≤25% signifies low hetero-
geneity, I2 ≤50% is moderate heterogeneity and I2 >50% is 
considered high heterogeneity.20 Small study effects and 
potential publication bias were examined by constructing 
funnel plots for the clinical outcomes in which the SE of 
the log of the risk ratio was plotted against the risk ratio 
(central estimate).21
Sensitivity analyses restricted to trials evaluating shorter 
durations of DAPT (≤3 months) were conducted to 
explore the primary outcome of all- cause mortality and 
the secondary efficacy and safety outcomes. A further 
sensitivity analysis was conducted to explore the effect of 
the type of P2Y12 inhibitor on study outcomes, restricting 
analysis to trials that used clopidogrel only or to studies 
that used any type of P2Y12 inhibitor (clopidogrel or pras-
ugrel or ticagrelor). Subgroup analysis evaluating the 
effect of clinical presentation was also performed from 
data in trials that reported risk ratios stratified by clin-
ical presentation. ACS was defined as patients suspected 
of acute myocardial infarction/ischaemia, and chronic 
coronary syndromes was defined as patients with stable 
symptoms of coronary artery disease.
Analysis was performed using R V.3.5.0 (R Foundation 
for Statistical Computing, Vienna, Austria) using the 
meta, metafor and metaviz packages.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation or writing of 
the report. The corresponding author had full access to 
all of the data and the final responsibility to submit for 
publication.
RESULTS
Our systematic search identified 44 424 articles and 
28 863 underwent title and abstract screening after dupli-
cates were removed (online supplemental S1 figure). Of 
these, 46 potentially eligible articles underwent full- text 
review, and a further 27 articles were excluded based on 
pre- specified criteria. A total of 19 randomised controlled 
trials from 2001 to 2018 with an overall population of 
60 111 patients (ranging from 870 to 15 968 in individual 
studies) were included. Of the total population, 33 952 
(56%) were ACS and 26 159 (44%) were chronic coro-
nary syndromes. Four randomised controlled trials eval-
uated duration of DAPT in ACS exclusively (n=8098), 
while 15 trials included both acute and chronic presenta-
tions. No randomised controlled trial investigating dura-
tion of DAPT in patients with ACS managed medically 
or undergoing coronary artery bypass graft surgery were 
identified.
The duration of DAPT across trials ranged from 
1 month to 24 months. Duration of follow- up also varied 
between trials ranging from 9 months to 24 months. Of 
the 19 included randomised controlled trials, eight trials 
compared shorter- term DAPT (≤3 months) with long- 
term DAPT (>12 months) with an overall population of 
38 036 patients and two of these studies included ACS 
presentations only (Table 1 and online supplemental S3 
table).
Risk of bias and publication bias
The risk of bias assessment was performed for each 
randomised controlled trial (online supplemental S4 
Figure 1 Forest plot showing overall pooled risk estimates according to outcomes of interest from all randomised controlled 
trials comparing short duration of dual- antiplatelet therapy (≤6 months) and long duration (≥12 months) included in this meta- 
analysis (n=60 111). DAPT, dual antiplatelet therapy.
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table). All studies were assessed as having low risk of bias 
for random sequence allocation (19/19, 100%) with 
majority of studies being low risk for allocation conceal-
ment (15/19, 79%), blinding of outcome assessment 
(15/19, 79%), incomplete outcome data (18/19, 95%), 
selective reporting (17/19, 90%) and other bias (18/19, 
95%). The majority of studies were identified to be at risk 
of bias due to inadequate blinding of participants and 
personnel (16/19, 84%). Allocation concealment was 
unclear in 3/19 (16%) studies. Evaluation of the funnel 
plots suggests a degree of publication bias when consid-
ering the safety outcomes of any bleeding and major 
bleeding (online supplemental S2 figure).
Short-term (≤6 months) versus long-term (≥12 months) dual 
antiplatelet therapy
All 19 randomised trials reported the primary outcome of 
all- cause mortality. Short- term DAPT was associated with 
an apparent decrease in all- cause mortality (RR: 0.90, 
95% CI: 0.81 to 1.01) (figure 1). There was no significant 
heterogeneity between studies when considering all- cause 
mortality (I2=0%). Individual trial data are presented in 
online supplemental S3 figure. A similar trend towards 
reduced all- cause mortality was observed with short- term 
DAPT in trials (n=8) which used different P2Y12 receptor 
antagonists including clopidogrel, ticagrelor or prasu-
grel (RR: 0.87, 95% CI: 0.76 to 1.00). While in an analysis 
restricted to studies (n=11) that used clopidogrel only as 
the P2Y12 receptor antagonist, the pooled risk estimates 
for all- cause mortality were equivalent (RR: 0.97, 95% CI: 
0.80 to 1.18) when considering DAPT duration online 
supplemental S4 figure.
All studies reported the efficacy end point of stroke, 
18 studies evaluated the secondary endpoints of myocar-
dial infarction and stent thrombosis, 16 and 12 studies 
reported cardiac mortality and coronary revasculari-
sation, respectively. A trend towards increased risk of 
myocardial infarction (RR: 1.09, 95% CI: 0.98 to 1.22) 
and equivalent risk of stent thrombosis (RR: 1.11, 
95% CI: 0.89 to 1.38) and coronary revascularisation 
(RR: 1.01, 95% CI: 0.93 to 1.11) was observed with short- 
term DAPT when compared with long- term DAPT (≥12 
months). Short- term DAPT was associated with similar 
risk of cardiac mortality (RR: 0.88, 95% CI: 0.72 to 1.08) 
and stroke (RR: 0.94, CI: 95% 0.77 to 1.14). There was no 
significant heterogeneity between studies when consid-
ering these efficacy outcomes (I2 <25%). Individual trial 
data are presented in online supplemental S3 figure.
Of the 19 studies, 18 reported the safety endpoint of 
major bleeding and 15 reported ‘any bleeding events’. 
Study- specific definitions are summarised in online 
supplemental S4 table. Short- term DAPT was associ-
ated with a reduction in bleeding when compared with 
long- term DAPT, with RR of 0.68 (95% CI: 0.55 to 0.83) 
for major bleeding and RR: 0.66 (95% CI: 0.56 to 0.77) 
for any bleeding. Modest heterogeneity (I2=32.2%) was 
observed across the studies when assessing these safety 
outcomes. Individual trial data are presented in online 
supplemental S3 figure.
Shorter duration (≤3 months) versus long-term (≥12 months) 
dual antiplatelet therapy
Meta- estimates were consistent in sensitivity analysis 
restricted to the eight trials comparing shorter dura-
tions of DAPT with long- term DAPT. The trend towards 
a reduction in all- cause mortality was maintained with 
shorter duration DAPT (RR: 0.91, 95% CI: 0.79 to 1.05) 
with no significant heterogeneity across the studies 
(I2=0%) (figure 2).
Figure 2 Forest plot showing pooled risk estimates according to outcomes of interest restricted to randomised controlled 
trials comparing even shorter duration of dual- antiplatelet therapy (≤3 months) and standard duration (12 months) included in 
this meta- analysis (n=38 036) DAPT, dual antiplatelet therapy.
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The pooled risk meta- estimates were equivalent for 
myocardial infarction (RR: 1.05, 95% CI: 0.93 to 1.19), 
stent thrombosis (RR: 1.05, 95% CI: 0.8 to 1.36), repeat 
revascularisation (RR: 1.0, 95% CI: 0.91 to 1.09) and 
stroke (RR: 0.95, 95% CI: 0.73 to 1.22). In shorter dura-
tion DAPT, estimates appeared to suggest a lower risk 
for cardiac death (RR: 0.82, 95% CI: 0.62 to 1.1). There 
was no significant heterogeneity between studies when 
considering these efficacy outcomes (I2 <10%).
Of the eight trials, seven reported results on major 
bleeding and any bleeding events. The observed reduc-
tion in major bleeding was maintained with shorter dura-
tion DAPT when compared with long- term DAPT (RR: 
0.64, 95% CI: 0.49 to 0.84). There was however high 
heterogeneity observed across these studies (I2=57.6%).
Duration of DAPT in acute or chronic coronary syndromes
Subgroup meta- analyses revealed a trend towards reduced 
risk of all- cause mortality with shorter duration DAPT in 
patients in whom the index presentation was ACS (RR: 
0.94, 95% CI: 0.76 to 1.16) and towards further reduced 
risk in those with chronic coronary syndrome (RR: 0.65, 
95% CI: 0.39 to 1.07). Risk estimates did not differ across 
the majority of efficacy outcomes with cardiac death, 
myocardial infarction, repeat revascularisation and 
stroke demonstrating equivalent risk ratios regardless of 
presentation (figure 3). There was an apparent increased 
risk of stent thrombosis in patients on shorter durations 
of DAPT presenting with ACS (RR: 1.49, 95% CI: 1.02 
to 2.17 for ACS and RR: 1.25, 95% CI: 0.44 to 3.58 for 
chronic coronary syndromes). There was no significant 
heterogeneity between studies when considering these 
outcomes (I2 <25%). Short duration DAPT was associ-
ated with a reduction in bleeding across subgroups, both 
for major bleeding (ACS RR: 0.69, 95% CI: 0.5 to 0.95, 
and chronic coronary syndrome RR: 0.41, 95% CI: 0.17 
to 0.99) and any bleeding (ACS RR: 0.66, 95% CI: 0.54 to 
0.81, and chronic coronary syndromes RR: 0.53, 95% CI: 
0.33 to 0.65).
DISCUSSION
We here report a systematic review and meta- analysis of 
19 randomised controlled trials evaluating the efficacy 
and safety of short- term DAPT compared with long- term 
DAPT. Our principal finding suggests a trend towards a 
reduced risk of all- cause mortality in patients who had 
short- term DAPT. This was true even when duration of 
therapy was reduced from ≤6 months to ≤3 months of 
DAPT, with no apparent increase in atherothrombotic 
events. Moreover, these observations were consistent 
when comparing patients who presented with acute or 
chronic coronary syndromes, with the exception of stent 
thrombosis where an increased risk was noted in those on 
shorter durations of DAPT for patients presenting acutely. 
These findings highlight the uncertainty regarding 
current guideline recommendations for a default strategy 
of 12 months of DAPT in patients with ACS.3 4
In a meta- analysis of 10 trials of patients with chronic 
coronary syndrome undergoing percutaneous coronary 
intervention, Palmerini and colleagues suggested that, 
while 6 months of DAPT resulted in increased rates of 
Figure 3 Forest plot showing pooled risk estimates according to outcomes of interest in subgroups of patients with acute 
coronary syndrome (red) (n=13 466) and chronic coronary syndrome (black) (n=4281) comparing short duration of dual- 
antiplatelet therapy (≤6 months) and long duration (12 months); (DAPT, dual antiplatelet therapy).
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myocardial infarction and stent thrombosis, this did not 
translate into a reduction in cardiovascular death when 
compared with 12 months of therapy.22 However, they 
observed lower all- cause mortality with the use of short- 
term DAPT driven by a lower risk of major bleeding and 
significant reduction in non- cardiovascular death. As 
a result of this meta- analysis, the European Society of 
Cardiology and the American Heart Association/Amer-
ican College of Cardiology guidance changed for patients 
with chronic coronary syndromes who underwent percu-
taneous coronary intervention to make 6 months of 
DAPT the standard of care. These observations did not 
influence recommendations on the duration of DAPT in 
ACS where these guidelines continue to recommend a 
12- month duration of therapy as standard of care.3 4
Yin and colleagues recently published a network meta- 
analysis comparing short- term (<6 months) with standard 
term (12 months) and longer- term (≥18 months) DAPT.6 
Their analysis included 17 studies and also reported a 
reduction all- cause mortality and fewer bleeding events 
in patients on short- term DAPT, despite including more 
studies that had enrolled patients with ACS. Their sensi-
tivity analysis comparing patients by acute or chronic 
presentation, demonstrated short- term DAPT had equiv-
alent safety and efficacy outcomes when compared with 
longer durations. Khan and colleagues conducted a 
network meta- analysis of 24 trials on patients requiring 
DAPT following percutaneous coronary intervention, 
which additionally compared outcomes in those on mid- 
term DAPT (6–12 months). They reported equivalent 
outcomes for all- cause mortality across groups, though 
a trend towards reduced risk in patients on short- term 
DAPT was noted. While risk ratios for myocardial infarc-
tion were reduced in long- term DAPT, this was again 
counter- balanced by an increase in bleeding events.23 Even 
in high- risk patients with diabetes mellitus, meta- analyses 
suggest equivalent rates of all- cause mortality, cardiac 
death and adverse cardiac events regardless of duration 
of DAPT.24 Our report is consistent with these recent 
meta- analyses. However, we have here included newer 
trials such as Kim et al and Mehran et al, which assessed 
shorter term DAPT (<3 months vs ≥12 months).8 25 In 
our analysis, shorter duration of DAPT (≤3 months) was 
associated with a trend towards lower all- cause mortality, 
remained similarly effective in key efficacy outcomes, but 
had substantially lower rates of bleeding when compared 
with long- term DAPT (≥12 months). While majority of 
trials evaluating duration of DAPT used clopidogrel, 
more recent trials have evaluated potent P2Y12 receptor 
antagonists.8 25 Similar to findings from Navarese et al, we 
observed a reduction in all- cause mortality with shorter 
durations of therapy in studies including potent P2Y12 
receptor antagonists compared with those that used 
clopidogrel only.26
Why should we consider 3 months of DAPT to be any 
different to 6 months of DAPT? Multiple trials in the 
patients with ACS have demonstrated high initial isch-
aemic event rates which revert to lower linear rates from 
3 months onwards.1 2 27 28 Consequently, the largest abso-
lute reductions in cardiovascular events are driven by the 
use of DAPT in the first 3 months after an ACS. Indeed, 
in the CURE trial, DAPT caused the majority of the 
reductions in recurrent myocardial infarction within the 
first 3 months with only modest benefits thereafter.29 In 
contrast, there was a persistent and continuous bleeding 
hazard that was not time dependent, suggesting that the 
prevention of myocardial infarction may become counter-
balanced by the hazards of bleeding beyond 3 months.29
Withdrawal of P2Y12 receptor antagonists from DAPT 
is associated with a rebound prothrombotic effect and is 
associated with an increase in rates of stent thrombosis.30 
We observed this phenomenon, especially in those with 
ACS randomised to a shorter duration of DAPT. Stent 
thrombosis does however occur irrespective of the timing 
of withdrawal as demonstrated in the DAPT trial where 
rebound stent thrombosis was seen after DAPT cessation 
at both 12 and 30 months.13 This perhaps emphasises 
the importance of procedural variables, such as optimal 
stent deployment especially in patients with ACS when 
deciding on the duration of DAPT. As such, a small but 
persistent risk of stent- thrombosis will persist when transi-
tioning from dual therapy to monotherapy whenever this 
occurs.
It should be noted that stent thrombosis occurs infre-
quently and did not correlate with increased mortality. 
Advances in stent technologies have reduced rates of 
stent thrombosis.31 Bleeding events on the other hand 
occur much more often, and the subsequent risk of all- 
cause mortality has been demonstrated in a wide variety 
of trials in patients with coronary artery disease regard-
less of trial intervention. For example, in trials of antico-
agulant therapy use in ACS, those therapies with a lower 
bleeding hazard have a lower all- cause mortality despite 
having similar efficacy in preventing atherothrombotic 
events.32 Moreover, trials of arterial access sites for percu-
taneous coronary intervention in ACS also demonstrate 
a mortality benefit that is attributable to lower rates of 
bleeding with radial artery access.33 34 This supports the 
notion that bleeding events are an important determi-
nant of all- cause mortality in patients receiving treatment 
for coronary artery disease and consequently, therapeutic 
approaches that minimise the risk of bleeding have the 
potential to reduce mortality in these patients.
Our systemic review and meta- analysis highlight the 
paucity of randomised controlled trial evidence to guide 
DAPT in patients with ACS who are managed without 
percutaneous coronary intervention such as those 
receiving medical therapy only or those undergoing 
coronary artery bypass grafting. Patients with ACS who 
are managed with medical therapy only are often at 
the extremes of risk with either an event attributable to 
minor coronary artery disease or multiple comorbidity 
and a contraindication to invasive coronary angiography. 
Registry data suggest between 20% and 40% of all admis-
sions for non- ST segment elevation myocardial infarc-
tions are managed medically and recurrent events can 
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be as much as three times more likely to occur in this 
population.35 36 The balance of bleeding and ischaemic 
risk is clearly challenging in these situations. For patients 
who are treated with coronary artery bypass graft surgery, 
DAPT is only offered to those with ACS, and following 
a brief interruption for surgery, are usually maintained 
on therapy for 12 months. Bleeding and ischaemic risk 
in these patients are likely to be affected by the surgical 
procedure itself and therefore they represent a group 
that is distinct from other patients with acute or chronic 
coronary syndromes. While meta- analyses show DAPT 
prevents graft occlusion, none have robustly assessed the 
optimum duration of therapy.37
It is important to acknowledge that randomised 
controlled trials rightly have strict entry and exclu-
sion criteria for their study participants. Patients with 
bleeding risks have been systematically excluded from 
these randomised controlled trials which report lower 
rates of bleeding and non- cardiovascular mortality than 
the general population.38 However, in real- world practice, 
clinicians make individual decisions with their patients 
on whether to initiate DAPT and this may include those 
who would otherwise not have been entered into clinical 
trials because of a history of bleeding. There is, therefore, 
a real concern that bleeding risk may be under appre-
ciated and bleeding events may be disproportionately 
greater with the wider use of DAPT in clinical practice. 
As such, we believe that there is a clear and pressing 
need to address what the optimum duration of DAPT is 
in a broad and unselected cohort of patients suffering 
ACS. Major randomised controlled trials, such as Dura-
tion of Dual Antiplatelet Therapy in Acute Coronary 
Syndrome (DUAL- ACS2), may help answer this question 
(NCT03252249).
We should acknowledge the limitations of our meta- 
analysis. First, the data were gathered, and conclusions 
drawn from study- level data, and the majority of trials 
included were designed to test for non- inferiority. Indi-
vidual patient- level data may have added further insights 
particularly when considering clinical presentations. 
Time to randomisation varied across the trials, as did 
duration of follow- up, which may affect the robustness of 
overall results. Different antiplatelet combinations were 
used, some with more potent P2Y12 receptor antagonists 
than others, and some discontinuing aspirin rather than 
P2Y12 receptor antagonists at the end of the DAPT treat-
ment period. The data gathered for our analysis of DAPT 
in ACS are derived mostly from subgroup analyses and 
may not be reflective of ‘real- world higher risk’ popula-
tions. As such, care should be taken when interpreting 
the results. Additionally, the majority of trials included 
were deemed to be at risk of bias due to inadequate 
blinding of participants and personnel. Finally, endpoint 
definitions varied across the studies leading to increased 
heterogeneity particularly when considering bleeding 
outcomes.
In conclusion, our systematic review and meta- analysis 
suggest that short- term (≤6 months) and shorter 
durations (≤3 months) of DAPT are associated with lower 
risk of bleeding, equivalent efficacy and a trend towards 
lower all- cause mortality. There remains major uncer-
tainty about the optimal duration of DAPT that requires 
to be resolved in future trials, particularly for patients 
with ACS, and those managed without percutaneous 
coronary intervention.
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